MYH16 and hypertrophic cardiomyopathy: Mavacamten (MAVA), formerly known as MYK-461 (MyoKardia), is an allosteric inhibitor of sarcomeric myosins identified in a small-molecule screening of potential drugs for the treatment of human hypertrophic cardiomyopathy (HCM; Green et al., 2016; Spudich et al., 2016; Alsulami and Marston, 2020).